430 related articles for article (PubMed ID: 22030942)
1. The NSAID dilemma: managing osteoarthritis in high-risk patients.
Roth SH; Anderson S
Phys Sportsmed; 2011 Sep; 39(3):62-74. PubMed ID: 22030942
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis.
Wang X; Tian HJ; Yang HK; Wanyan P; Peng YJ
Eur J Gastroenterol Hepatol; 2011 Oct; 23(10):876-80. PubMed ID: 21900785
[TBL] [Abstract][Full Text] [Related]
3. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
[TBL] [Abstract][Full Text] [Related]
4. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
[TBL] [Abstract][Full Text] [Related]
5. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
Scheiman JM; Hindley CE
Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
[TBL] [Abstract][Full Text] [Related]
6. Osteoarthritis therapy--are there still unmet needs?
Laufer S
Rheumatology (Oxford); 2004 Feb; 43 Suppl 1():i9-15. PubMed ID: 14752170
[TBL] [Abstract][Full Text] [Related]
7. The use of NSAIDs in rheumatic disorders 2005: a global perspective.
Kean WF; Buchanan WW
Inflammopharmacology; 2005; 13(4):343-70. PubMed ID: 16354389
[TBL] [Abstract][Full Text] [Related]
8. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs.
Hur C; Chan AT; Tramontano AC; Gazelle GS
Ann Pharmacother; 2006 Jun; 40(6):1052-63. PubMed ID: 16720709
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance.
Borer JS; Simon LS
Arthritis Res Ther; 2005; 7 Suppl 4(Suppl 4):S14-22. PubMed ID: 16168077
[TBL] [Abstract][Full Text] [Related]
10. Balancing risks and benefits of cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs.
Scheiman JM
Gastroenterol Clin North Am; 2009 Jun; 38(2):305-14. PubMed ID: 19446260
[TBL] [Abstract][Full Text] [Related]
11. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference.
Tannenbaum H; Bombardier C; Davis P; Russell AS;
J Rheumatol; 2006 Jan; 33(1):140-57. PubMed ID: 16331802
[TBL] [Abstract][Full Text] [Related]
12. [Cardiovascular and gastrointestinal risks associated with selective and non-selective NSAIDs].
van den Bemt BJ; Benraad HB; Rasker JJ
Ned Tijdschr Geneeskd; 2007 May; 151(19):1062-7. PubMed ID: 17552414
[TBL] [Abstract][Full Text] [Related]
13. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
[TBL] [Abstract][Full Text] [Related]
14. Minimizing risks of NSAIDs: cardiovascular, gastrointestinal and renal.
Davies NM; Reynolds JK; Undeberg MR; Gates BJ; Ohgami Y; Vega-Villa KR
Expert Rev Neurother; 2006 Nov; 6(11):1643-55. PubMed ID: 17144779
[TBL] [Abstract][Full Text] [Related]
15. Primer: managing NSAID-induced ulcer complications--balancing gastrointestinal and cardiovascular risks.
Chan FK
Nat Clin Pract Gastroenterol Hepatol; 2006 Oct; 3(10):563-73. PubMed ID: 17008926
[TBL] [Abstract][Full Text] [Related]
16. Practical approaches to minimizing gastrointestinal and cardiovascular safety concerns with COX-2 inhibitors and NSAIDs.
Scheiman JM; Fendrick AM
Arthritis Res Ther; 2005; 7 Suppl 4(Suppl 4):S23-9. PubMed ID: 16168078
[TBL] [Abstract][Full Text] [Related]
17. When should COX-2 selective NSAIDs be used for osteoarthritis and rheumatoid arthritis?
Lo V; Meadows SE; Saseen J
J Fam Pract; 2006 Mar; 55(3):260-2. PubMed ID: 16510063
[TBL] [Abstract][Full Text] [Related]
18. COX-2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors.
van der Linden MW; Gaugris S; Kuipers EJ; van Herk-Sukel MP; van den Bemt BJ; Sen SS; Herings RM
Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):880-90. PubMed ID: 19593747
[TBL] [Abstract][Full Text] [Related]
19. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks.
Rostom A; Moayyedi P; Hunt R;
Aliment Pharmacol Ther; 2009 Mar; 29(5):481-96. PubMed ID: 19053986
[TBL] [Abstract][Full Text] [Related]
20. Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study.
Lanas A; Tornero J; Zamorano JL
Ann Rheum Dis; 2010 Aug; 69(8):1453-8. PubMed ID: 20498210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
